Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events

Steven Pipe, MD, Margaret V. Ragni, MD MPH, Claude Négrier, MD PhD, Qifeng Yu, PhD, Naghmana Bajwa, MD, John Caminis, MD, Baisong Mei, MD PhD, Shauna R. Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 1138.

https://doi.org/10.1182/blood-2019-124108

Published: 2019

Journal Articles

Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab

Yesim Dargaud, MD PhD, Anne Lienhart, MD, Nathalie Enjolras, PhD, Claude Negrier, MD

Blood (2017) 130 (Supplement 1): 3675.

https://doi.org/10.1182/blood.V130.Suppl_1.3675.3675

Published: 2017

Journal Articles

Perioperative Management in Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

Claude Negrier, MD, Margaret V. Ragni, MD MPH, Pencho Georgiev, MD, Toshko Jelev Lissitchkov, MD PhD, Huy Van Nguyen, PharmD, Kate Madigan, K John Pasi

Blood (2017) 130 (Supplement 1): 2366.

https://doi.org/10.1182/blood.V130.Suppl_1.2366.2366

Published: 2017

Journal Articles

Genetic Fusion to Factor XIII B-Subunit Improves the Pharmacokinetic Properties of Factor IX

Sandra Le Quellec, MD, Nathalie Enjolras, PhD, Jean-Claude Bordet, Vladmir Jacqueline, Claude Negrier, MD, Yesim Dargaud, MD PhD

Blood (2017) 130 (Supplement 1): 2339.

https://doi.org/10.1182/blood.V130.Suppl_1.2339.2339

Published: 2017

Journal Articles

Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Yesim G. Dargaud, MDPhD, Robert Klamroth, Luminita Rusen, MD, Jerzy Windyga, MD, Johann Bichler, PhD, Sigurd Knaub, Claude Negrier, MD

Blood (2016) 128 (22): 1410.

https://doi.org/10.1182/blood.V128.22.1410.1410

Published: 2016

Journal Articles

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Ana Rosa Cid, MD, Carmen Escuriola, MD, Cedric R. Hermans, MD PhD MRCP, Pal André Holme, PhD MD, Claude Negrier, MD, Savita Rangarajan, Angiola Rocino, Jerzy Windyga, MD, Alessandro Gringeri, MD MSc, Roberto Crea, DVM, MSc

Blood (2016) 128 (22): 5038.

https://doi.org/10.1182/blood.V128.22.5038.5038

Published: 2016

Journal Articles

Effect of Five Therapeutic Strategies on the Coagulation Defect Induced By the Thrombomodulin C.1611C>a Mutation

Yesim G. Dargaud, MDPhD, Yohann Jourdy, Sandra Le Quellec, Coen Hemker, Theo Lindhout, Elisabetta Castoldi, Claude Negrier, MD

Blood (2015) 126 (23): 2287.

https://doi.org/10.1182/blood.V126.23.2287.2287

Published: 2015

Journal Articles

Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Claude Negrier, MD, Lynda Mae Lepatan, MD, Faralzah Karim, MD, Anne Lienhart, MD, Denise Wolko, Christine Voigt, PhD, Iris C. Jacobs, MD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 2298.

https://doi.org/10.1182/blood.V126.23.2298.2298

Published: 2015

Journal Articles

The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?

Yesim G. Dargaud, MDPhD, Marc Fouassier, MD, Sophie Ducastelle, MD, Philippe Moreau, MD, Charles Dumontet, MD PhD, Mauricette Michallet, MD PhD, Jean-Claude Bordet, Claude Negrier, MD PhD

Blood (2014) 124 (21): 2037.

https://doi.org/10.1182/blood.V124.21.2037.2037

Published: 2014

Journal Articles

Effect of Pre-Analytical Conditions On the Results of Thrombodynamics Assay

Natalia M. Dashkevich, Tatiana V. Vuimo, Anna N. Balandina, Ruzanna A. Ovsepyan, Natalia P. Soshitova, Elena A. Seregina, Stepan S. Surov, Elena N. Lipets, Mikhail A. Panteleev, Fazoil I Ataullakhanov, Claude Negrier, MD

Blood (2012) 120 (21): 4393.

https://doi.org/10.1182/blood.V120.21.4393.4393

Published: 2012

Journal Articles

The Impact of Factor IX Level on Thrombin Generation and Bleeding During Warfarin Anticoagulation

Yesim Dargaud, Maureane Hoffman, MD, PhD, Claude Negrier, MD, Leana Lefrapper, Dougald M. Monroe, III, PhD

Blood (2011) 118 (21): 541.

https://doi.org/10.1182/blood.V118.21.541.541

Published: 2011

Journal Articles

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

Cindy A. Leissinger, MD, Eric Berntorp, MD, Chiara Biasioli, MD, Shannon Carpenter, MD, MS, Hyejin Jo, MS, Kaan Kavakli, MD, Claude Negrier, MD, Angiola Rocino, MD, Jerzy Windyga, MD, Bulent Zulfikar, MD, Alessandro Gringeri, MD

Blood (2010) 116 (21): 720.

https://doi.org/10.1182/blood.V116.21.720.720

Published: 2010

Journal Articles

Hepatoma Cell Line HuH-7 : a Promising New Cellular System for Recombinant FIX Production.

Nathalie Enjolras, PhD, Yesim Dargaud, MD, PhD, Jean-Luc Plantier, PhD, Heli Simpson, Florine Guillaume, Claude Negrier, MD

Blood (2009) 114 (22): 4202.

https://doi.org/10.1182/blood.V114.22.4202.4202

Published: 2009

Journal Articles

How can We Predict Efficacy of rFVIIa in Hemophilia Patients with Inhibitors?

Yesim Dargaud, MD, PhD, Jean C Bordet, Chantal Huchon, Claude Negrier, MD

Blood (2009) 114 (22): 3487.

https://doi.org/10.1182/blood.V114.22.3487.3487

Published: 2009

Journal Articles

Substitution of Four Residues Revealed by High-Throughput Screening of Human Factor VIII A2 Domain Generated a Recombinant Molecule That Escapes to Anti-Factor VIII Antibodies

Jean-Luc Plantier, Didier Saboulard, Marc Delcourt, Nathalie Enjolras, Claude Negrier, MD

Blood (2008) 112 (11): 3067.

https://doi.org/10.1182/blood.V112.11.3067.3067

Published: 2008

Journal Articles

Inactivation-Resistant Recombinant Factor VIII Exhibits Superior Thrombin Generation Capacity in Comparison to Wild-Type and B Domain-Deleted Factor VIII.

Joshua Russell, Yesim Dargaud, MD, Randal J. Kaufman, PhD, Claude Negrier, MD, PhD, Steven W. Pipe, MD

Blood (2006) 108 (11): 1604.

https://doi.org/10.1182/blood.V108.11.1604.1604

Published: 2006

Journal Articles

Generation of Factor VIII Molecules Partially Resistant to Activated Protein C.

Veronique Rolli, Ph D, Nathalie Enjolras, PhD, Cecile Ducasse, Marie-Helene Rodriguez, PhD, Thomas Weimer, PhD, Hans-Peter Hauser, PhD, Claude Negrier, MD, PhD, Jean-Luc Plantier, Ph D

Blood (2004) 104 (11): 1729.

https://doi.org/10.1182/blood.V104.11.1729.1729

Published: 2004

NARROW

Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events

Individually Tailored By-Passing Therapy for the Management of Breakthrough Bleeds in Hemophilia Patients with Inhibitors Receiving Prophylaxis with Emicizumab

Perioperative Management in Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

Genetic Fusion to Factor XIII B-Subunit Improves the Pharmacokinetic Properties of Factor IX

Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Effect of Five Therapeutic Strategies on the Coagulation Defect Induced By the Thrombomodulin C.1611C>a Mutation

Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?

Effect of Pre-Analytical Conditions On the Results of Thrombodynamics Assay

The Impact of Factor IX Level on Thrombin Generation and Bleeding During Warfarin Anticoagulation

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

Hepatoma Cell Line HuH-7 : a Promising New Cellular System for Recombinant FIX Production.

How can We Predict Efficacy of rFVIIa in Hemophilia Patients with Inhibitors?

Substitution of Four Residues Revealed by High-Throughput Screening of Human Factor VIII A2 Domain Generated a Recombinant Molecule That Escapes to Anti-Factor VIII Antibodies

Inactivation-Resistant Recombinant Factor VIII Exhibits Superior Thrombin Generation Capacity in Comparison to Wild-Type and B Domain-Deleted Factor VIII.

Generation of Factor VIII Molecules Partially Resistant to Activated Protein C.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only